Challenges in the quality of herbal medicinal products with a specific focus on contaminants

被引:4
|
作者
Steinhoff, Barbara [1 ]
机构
[1] Bundesverband Arzneimittel Hersteller eV BAH, Dept Herbal & Homoeopath Med Prod, Ubierstr 71-73, D-53173 Bonn, Germany
关键词
contaminants; elemental impurities; herbal medicinal products; pesticide residue; pyrrolizidine alkaloids;
D O I
10.1002/pca.2879
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background The complex regulatory framework for the quality of herbal medicinal products, in particular with regard to potential contaminants, consists of legal provisions including Pharmacopoeia requirements, relating to limits as well as in most cases to methods for determination. Objective This review intends to provide an overview on the legal requirements for testing potential contaminants in herbal drugs used for the production of herbal medicinal products. Methodology The following issues are described and discussed: For the assessment of pesticide residues, Chapter 2.8.13 of the European Pharmacopoeia and Regulation (EC) 396/2005 applies, for heavy metals the general Pharmacopoeia monograph as well as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q3D guideline on elemental impurities. The Pharmacopoeia also includes limits and acceptance criteria for microbiological purity and aflatoxins, respectively. Polycyclic aromatic hydrocarbons are mentioned in Regulation (EC) 1881/2006 for food as well as in a Reflection Paper on herbal medicinal products. For several years, a potential contamination with pyrrolizidine alkaloids was discussed which led to measures being imposed on industry and health authorities. Results Various examples demonstrate that the evaluation of data from daily analytical practice is extremely useful to gain an overview on the occurrence of residues and/or contaminants in herbal drugs and herbal preparations. Such evaluations might assist manufacturers in their individual risk assessment and the definition of their testing strategies and contribute to guarantee the quality and safety of the marketed products. Conclusion Annual data evaluations demonstrate that a remarkable decrease of the pyrrolizidine alkaloid content burden in herbal drugs and extracts used for the production of herbal medicinal products has been achieved over the past few years. However, it has also become clear that this issue cannot be completely solved in the near future.
引用
收藏
页码:117 / 123
页数:7
相关论文
共 50 条
  • [1] CONTAMINANTS OF MEDICINAL HERBS AND HERBAL PRODUCTS
    Kosalec, Ivan
    Cvek, Josipa
    Tomic, Sinisa
    [J]. ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2009, 60 (04): : 485 - 501
  • [2] Legal requirements for the control of contaminants in herbal medicinal products
    Steinhoff, B.
    [J]. PLANTA MEDICA, 2011, 77 (12) : 1242 - 1242
  • [3] The microbiological quality of herbal teas and herbal medicinal products
    Bosnic, T.
    Softic, D. Z.
    Jery-Simanovic, D.
    Pilipovic, S.
    [J]. PLANTA MEDICA, 2007, 73 (09) : 897 - 897
  • [4] Supermolecules as a quality markers of herbal medicinal products
    Cheng, Wenhui
    Li, Shuang
    Han, Jiyang
    Su, Jin
    Cai, Wei
    [J]. HELIYON, 2022, 8 (12)
  • [5] Quality requirements for herbal medicinal products in Europe
    Franz, G
    [J]. COMPLEMENTARY AND ALTERNATIVE APPROACHES TO BIOMEDICINE, 2004, 546 : 43 - 56
  • [6] The significance of quality for efficacy and safety of herbal medicinal products
    Busse, W
    [J]. DRUG INFORMATION JOURNAL, 2000, 34 (01): : 15 - 23
  • [7] New frontiers in the quality of herbal medicinal products (HMPs)
    Vlietinck, A.
    [J]. PLANTA MEDICA, 2008, 74 (09) : 904 - 904
  • [8] The Significance of Quality for Efficacy and Safety of Herbal Medicinal Products
    Werner Busse
    [J]. Drug information journal : DIJ / Drug Information Association, 2000, 34 : 15 - 23
  • [9] QUALITY OF HERBAL MEDICINAL PRODUCTS: CONTRIBUTION OF THE EUROPEAN PHARMACOPOEIA
    Canigueral, S.
    Vila, R.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 15 - 15
  • [10] Quality of herbal medicinal products and implications for safety and efficacy
    Vlietinck, AJ
    [J]. DRUG SAFETY, 2006, 29 (04) : 348 - 348